Latest Zynex Inc (ZYXI) Headlines Zynex Non-Ste
Post# of 76
Posted On: 03/12/2014 6:26:48 AM
Latest Zynex Inc (ZYXI) Headlines
Zynex Non-Sterile Compound Pharmacy Attains Licensing in 19 States
Marketwire - Mon Mar 03, 7:01AM CST
Zynex, Inc. (OTCQB: ZYXI), a medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today that its subsidiary Zynex Medical, recently received its 19th state license for its non-sterile compound pharmacy.
Zynex Expands Electrotherapy Product Sales Channel
Marketwire - Tue Feb 11, 7:02AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation and neurological diagnostics announces that it signed a strategic sales and marketing agreement with Total Care Marketing, LLC to sell its primary electrotherapy device, the NexWave, through Total Care Marketing's sales organization.
Zynex Receives Roszdravnadzor (Russian Equivalent of FDA) Clearance to Market Neuromove(TM) Stroke Recovery Device and NexWave(TM) Electrotherapy Device in Russia
Marketwire - Thu Feb 06, 7:00AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation and neurological diagnosis, announced today that Russia's Federal Service on Surveillance in Healthcare (Roszdravnadzor) has granted clearance to market its NeuroMove(TM) stroke recovery device and NexWave(TM) electrotherapy device.
ZTE, JD.com Sign CNY3.5bn Agreement
SinoCast - Fri Jan 17, 4:48AM CST
ZTE Corporation January 16 signed a CNY 3.5 billion strategic cooperation agreement with JD.com, which showed that the two will jointly launch the Youth mobile phones.
Zynex Appoints Vice President of Sales for NeuroDiagnostics Division
Marketwire - Tue Jan 07, 7:00AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation, and neurological diagnosis, announced today that it has appointed James Carter as Vice President of Sales for its NeuroDiagnostics division.
Zynex Signs Distribution Agreement for China Market
Marketwire - Tue Dec 24, 7:30AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation and neurological diagnosis, announced today that it signed a five-year exclusive distribution agreement with DIH Medical Technologies Co Ltd for the distribution of its NeuroMove device in China commencing December 17, 2013. Although the agreement can be cancelled upon 60 days' notice by DIH, the minimum purchase requirements over the agreements expected five-year term would equal sales of $4.6 million. The first year's minimum commitment is $750,000.
Zynex Announces Investor Relations Initiative
Marketwire - Fri Dec 20, 8:30AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation, and neurological diagnosis, announced today that it has enabled Level 2 quote visibility for investors though the OTC Markets Group.
Zynex Announces CEO Interview With The Wall Street Analyst
Marketwire - Fri Dec 06, 7:00AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced that The Wall Street Analyst conducted an audio interview with Zynex's CEO, Thomas Sandgaard.
Zynex Introduces TENSWave Medical Device
Marketwire - Mon Nov 25, 7:00AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced the introduction of its next generation electrotherapy medical device, the TENSWave.
Zynex Medical Receives 2013 Colorado Excellence Award
Marketwire - Tue Nov 19, 7:02AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced today that they are the recipient of the Small Business Institute for Excellence in Commerce's (SBIEC) 2013 Colorado Excellence Award.
Zynex Ranked 15th in Revenue Growth Among Medical Device Companies
Marketwire - Mon Nov 18, 7:00AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced today that it has been ranked 15th in revenue growth among all medical device companies in the US and Canada on Deloitte's 2013 Technology Fast 500. The company was ranked 7th in 2012.
Zynex Announces Third Quarter 2013 Financial Results
Marketwire - Thu Nov 07, 7:00AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announces its third quarter 2013 financial results.
Global Neuromodulation Market Report 2013 - 2017
M2 - Wed Nov 06, 4:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/nfb62c/neuromodulation) has announced the addition of the "Global Neuromodulation Market Report 2013 - 2017" report to their offering. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS). The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed leads are connected by means of an extension cable to a pulse generator to generate electrical stimulation. Neuromodulation can have applications in any area of the body and can treat several diseases like chronic pain, epilepsy, psychiatric disorder, movement disorder, cardiovascular disorder, genitourinary and colorectal disorder, stroke and brain injury, and gastric disorder. The main drivers for the neuromodulation market are the rising population of aged people and age-related diseases like Alzheimer's, epilepsy, spinal cord injury, and Parkinson's disease. According to the International Neuromodulation Society, about 40 million to 50 million patients worldwide suffer from epilepsy, and 1.5 million people currently (2012) suffer from Parkinson disease in the U.S. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 3.1 Introduction 3.2 Market Segmentation 3.3 Market Dynamics 3.4 Restraints 3.5 Market Share Analysis 4 Global Neuromodulation Market (Internal & External) 5 Geographic Analysis 5.1 Introduction 5.2 North America 5.3 Europe 5.4 Asia 5.5 Rest Of The World 6 Competitive Landscape 6.1 Introduction 6.2 Agreements, Partnerships, Collaborations, Contracts & Joint Ventures 6.3 New Product Launch 6.4 Expansion 6.5 Other Developments 6.6 Approvals 7 Company Profiles Companies Mentioned - Anm Adaptive Neuromodulation Gmbh - Biocontrol Medical, Ltd. - Boston Scientific Corporation - Cerbomed Gmbh - Cyberonics, Inc. - Endostim, Inc. - Enteromedics, Inc. - The Magstim Company Limited - Medtronic, Inc. - Neuronetics, Inc. - Neuropace, Inc. - Neurosigma, Inc. - Nevro Corporation - Rs Medical - Spinal Modulation, Inc. - St. Jude Medical - Synapse Biomedical, Inc. - Uroplasty, Inc. - Zynex, Inc. For more information visit http://www.researchandmarkets.com/research/nf...modulation
Zynex Schedules Third Quarter 2013 Earnings Conference Call and Webcast
Marketwire - Thu Oct 31, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced today that it will host an investor webcast, Thursday, November 7, 2013 at 9:00 a.m. Mountain Time - 11:00 a.m. Eastern Time to discuss the Company's third quarter 2013 results.
Zynex Receives SFDA Clearance to Market Neuromove(TM) Stroke Recovery Device in China
Marketwire - Thu Oct 24, 7:01AM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced today that China's State Food and Drug Administration (SFDA) has granted clearance to market its NeuroMove(TM) stroke recovery device.
Zynex Announces Second Quarter 2013 Financial Results
Marketwire - Thu Aug 08, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announces its second quarter 2013 financial results.
Zynex Schedules Second Quarter 2013 Earnings Conference Call and Webcast
Marketwire - Thu Aug 01, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced today that it will host an investor webcast, Thursday, August 8, 2013 at 9:00 a.m. Mountain Time - 11:00 a.m. Eastern Time to discuss the Company's second quarter 2013 results.
Zynex Signs Strategic Agreement With Advanced Brain Monitoring, Expands Presence in Sleep Diagnostic Market
Marketwire - Mon Jul 22, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnostics and cardiac monitoring, announces that it signed a strategic sales, marketing and distribution agreement with California based Advanced Brain Monitoring.
The Neuromodulation Devices Market - Rising Numbers For Cases of Alzheimer's, Epilepsy, and Parkinson's Disease Leading to High Demand for Non-Invasive Treatments
M2 - Thu Jul 18, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s7pvwv/neuromodulation) has announced the addition of the "The Neuromodulation Devices Market" report to their offering. The main drivers for the neuromodulation market are the rising population of aged people and age-related diseases like Alzheimer's, epilepsy, spinal cord injury, and Parkinson's disease. According to the International Neuromodulation Society, about 40 million to 50 million patients worldwide suffer from epilepsy, and 1.5 million people currently (2012) suffer from Parkinson disease in the U.S. The large pool of patients that suffer from depression, stroke, anxiety disorders, lower back pain, urinary incontinence, and tremor offers the neuromodulation industry opportunities to grow in the next five years. The market for treatment of tinnitus, in particular, represents an emerging application of neuromodulation. According to the American Tinnitus Association, about 50 million people currently (2012) suffer from this disease in the U.S. Neuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for minimally invasive and non-invasive treatment. With advancements in technology, neuromodulation is expected to become a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart failure, headache, depression, epilepsy, etc. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS). The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed leads are connected by means of an extension cable to a pulse generator to generate electrical stimulation. Neuromodulation can have applications in any area of the body and can treat several diseases like chronic pain, epilepsy, psychiatric disorder, movement disorder, cardiovascular disorder, genitourinary and colorectal disorder, stroke and brain injury, and gastric disorder. This report estimates the market for six major segments, namely, spinal cord stimulation, deep brain stimulation, sacral nerve stimulation, vagus nerve stimulation, gastric electrical stimulation, transcranial magnetic stimulation, and others. The report also estimates the market for different neuromodulation techniques as well as geographic analysis of each segment in North America, Europe, Asia-Pacific, and Rest of the World. As technologies develop and the number of trained physician increases, the likelihood of neuromodulation being seen as life-changing treatment will increase dramatically. It is estimated that the market for neuromodulation will be shared largely by deep brain stimulation and spinal cord stimulation. The key players in the neuromodulation devices market are Medtronic, Inc. (U.S.), Cyberonics, Inc. (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical (U.S.), Enteromedics, Inc (U.S.), Neuropace, Inc (U.S.), Zynex, Inc (U.S.) and Neuronetics, Inc (U.S.). The emerging players in this market are Functional Neuromodulation, Ltd (U.S.), Microtransponder (U.S.), and Neurosigma, Inc (U.S.). For more information visit http://www.researchandmarkets.com/research/s7...modulation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Zynex Updates Financial Outlook for 2013
Marketwire - Fri Jul 12, 2:25PM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced today the Company's updated financial outlook for the remainder of 2013.
Zynex Non-Sterile Compound Pharmacy Attains Licensing in 19 States
Marketwire - Mon Mar 03, 7:01AM CST
Zynex, Inc. (OTCQB: ZYXI), a medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today that its subsidiary Zynex Medical, recently received its 19th state license for its non-sterile compound pharmacy.
Zynex Expands Electrotherapy Product Sales Channel
Marketwire - Tue Feb 11, 7:02AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation and neurological diagnostics announces that it signed a strategic sales and marketing agreement with Total Care Marketing, LLC to sell its primary electrotherapy device, the NexWave, through Total Care Marketing's sales organization.
Zynex Receives Roszdravnadzor (Russian Equivalent of FDA) Clearance to Market Neuromove(TM) Stroke Recovery Device and NexWave(TM) Electrotherapy Device in Russia
Marketwire - Thu Feb 06, 7:00AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation and neurological diagnosis, announced today that Russia's Federal Service on Surveillance in Healthcare (Roszdravnadzor) has granted clearance to market its NeuroMove(TM) stroke recovery device and NexWave(TM) electrotherapy device.
ZTE, JD.com Sign CNY3.5bn Agreement
SinoCast - Fri Jan 17, 4:48AM CST
ZTE Corporation January 16 signed a CNY 3.5 billion strategic cooperation agreement with JD.com, which showed that the two will jointly launch the Youth mobile phones.
Zynex Appoints Vice President of Sales for NeuroDiagnostics Division
Marketwire - Tue Jan 07, 7:00AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation, and neurological diagnosis, announced today that it has appointed James Carter as Vice President of Sales for its NeuroDiagnostics division.
Zynex Signs Distribution Agreement for China Market
Marketwire - Tue Dec 24, 7:30AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation and neurological diagnosis, announced today that it signed a five-year exclusive distribution agreement with DIH Medical Technologies Co Ltd for the distribution of its NeuroMove device in China commencing December 17, 2013. Although the agreement can be cancelled upon 60 days' notice by DIH, the minimum purchase requirements over the agreements expected five-year term would equal sales of $4.6 million. The first year's minimum commitment is $750,000.
Zynex Announces Investor Relations Initiative
Marketwire - Fri Dec 20, 8:30AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation, and neurological diagnosis, announced today that it has enabled Level 2 quote visibility for investors though the OTC Markets Group.
Zynex Announces CEO Interview With The Wall Street Analyst
Marketwire - Fri Dec 06, 7:00AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced that The Wall Street Analyst conducted an audio interview with Zynex's CEO, Thomas Sandgaard.
Zynex Introduces TENSWave Medical Device
Marketwire - Mon Nov 25, 7:00AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced the introduction of its next generation electrotherapy medical device, the TENSWave.
Zynex Medical Receives 2013 Colorado Excellence Award
Marketwire - Tue Nov 19, 7:02AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced today that they are the recipient of the Small Business Institute for Excellence in Commerce's (SBIEC) 2013 Colorado Excellence Award.
Zynex Ranked 15th in Revenue Growth Among Medical Device Companies
Marketwire - Mon Nov 18, 7:00AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced today that it has been ranked 15th in revenue growth among all medical device companies in the US and Canada on Deloitte's 2013 Technology Fast 500. The company was ranked 7th in 2012.
Zynex Announces Third Quarter 2013 Financial Results
Marketwire - Thu Nov 07, 7:00AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announces its third quarter 2013 financial results.
Global Neuromodulation Market Report 2013 - 2017
M2 - Wed Nov 06, 4:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/nfb62c/neuromodulation) has announced the addition of the "Global Neuromodulation Market Report 2013 - 2017" report to their offering. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS). The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed leads are connected by means of an extension cable to a pulse generator to generate electrical stimulation. Neuromodulation can have applications in any area of the body and can treat several diseases like chronic pain, epilepsy, psychiatric disorder, movement disorder, cardiovascular disorder, genitourinary and colorectal disorder, stroke and brain injury, and gastric disorder. The main drivers for the neuromodulation market are the rising population of aged people and age-related diseases like Alzheimer's, epilepsy, spinal cord injury, and Parkinson's disease. According to the International Neuromodulation Society, about 40 million to 50 million patients worldwide suffer from epilepsy, and 1.5 million people currently (2012) suffer from Parkinson disease in the U.S. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 3.1 Introduction 3.2 Market Segmentation 3.3 Market Dynamics 3.4 Restraints 3.5 Market Share Analysis 4 Global Neuromodulation Market (Internal & External) 5 Geographic Analysis 5.1 Introduction 5.2 North America 5.3 Europe 5.4 Asia 5.5 Rest Of The World 6 Competitive Landscape 6.1 Introduction 6.2 Agreements, Partnerships, Collaborations, Contracts & Joint Ventures 6.3 New Product Launch 6.4 Expansion 6.5 Other Developments 6.6 Approvals 7 Company Profiles Companies Mentioned - Anm Adaptive Neuromodulation Gmbh - Biocontrol Medical, Ltd. - Boston Scientific Corporation - Cerbomed Gmbh - Cyberonics, Inc. - Endostim, Inc. - Enteromedics, Inc. - The Magstim Company Limited - Medtronic, Inc. - Neuronetics, Inc. - Neuropace, Inc. - Neurosigma, Inc. - Nevro Corporation - Rs Medical - Spinal Modulation, Inc. - St. Jude Medical - Synapse Biomedical, Inc. - Uroplasty, Inc. - Zynex, Inc. For more information visit http://www.researchandmarkets.com/research/nf...modulation
Zynex Schedules Third Quarter 2013 Earnings Conference Call and Webcast
Marketwire - Thu Oct 31, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced today that it will host an investor webcast, Thursday, November 7, 2013 at 9:00 a.m. Mountain Time - 11:00 a.m. Eastern Time to discuss the Company's third quarter 2013 results.
Zynex Receives SFDA Clearance to Market Neuromove(TM) Stroke Recovery Device in China
Marketwire - Thu Oct 24, 7:01AM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced today that China's State Food and Drug Administration (SFDA) has granted clearance to market its NeuroMove(TM) stroke recovery device.
Zynex Announces Second Quarter 2013 Financial Results
Marketwire - Thu Aug 08, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announces its second quarter 2013 financial results.
Zynex Schedules Second Quarter 2013 Earnings Conference Call and Webcast
Marketwire - Thu Aug 01, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced today that it will host an investor webcast, Thursday, August 8, 2013 at 9:00 a.m. Mountain Time - 11:00 a.m. Eastern Time to discuss the Company's second quarter 2013 results.
Zynex Signs Strategic Agreement With Advanced Brain Monitoring, Expands Presence in Sleep Diagnostic Market
Marketwire - Mon Jul 22, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnostics and cardiac monitoring, announces that it signed a strategic sales, marketing and distribution agreement with California based Advanced Brain Monitoring.
The Neuromodulation Devices Market - Rising Numbers For Cases of Alzheimer's, Epilepsy, and Parkinson's Disease Leading to High Demand for Non-Invasive Treatments
M2 - Thu Jul 18, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s7pvwv/neuromodulation) has announced the addition of the "The Neuromodulation Devices Market" report to their offering. The main drivers for the neuromodulation market are the rising population of aged people and age-related diseases like Alzheimer's, epilepsy, spinal cord injury, and Parkinson's disease. According to the International Neuromodulation Society, about 40 million to 50 million patients worldwide suffer from epilepsy, and 1.5 million people currently (2012) suffer from Parkinson disease in the U.S. The large pool of patients that suffer from depression, stroke, anxiety disorders, lower back pain, urinary incontinence, and tremor offers the neuromodulation industry opportunities to grow in the next five years. The market for treatment of tinnitus, in particular, represents an emerging application of neuromodulation. According to the American Tinnitus Association, about 50 million people currently (2012) suffer from this disease in the U.S. Neuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for minimally invasive and non-invasive treatment. With advancements in technology, neuromodulation is expected to become a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart failure, headache, depression, epilepsy, etc. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS). The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed leads are connected by means of an extension cable to a pulse generator to generate electrical stimulation. Neuromodulation can have applications in any area of the body and can treat several diseases like chronic pain, epilepsy, psychiatric disorder, movement disorder, cardiovascular disorder, genitourinary and colorectal disorder, stroke and brain injury, and gastric disorder. This report estimates the market for six major segments, namely, spinal cord stimulation, deep brain stimulation, sacral nerve stimulation, vagus nerve stimulation, gastric electrical stimulation, transcranial magnetic stimulation, and others. The report also estimates the market for different neuromodulation techniques as well as geographic analysis of each segment in North America, Europe, Asia-Pacific, and Rest of the World. As technologies develop and the number of trained physician increases, the likelihood of neuromodulation being seen as life-changing treatment will increase dramatically. It is estimated that the market for neuromodulation will be shared largely by deep brain stimulation and spinal cord stimulation. The key players in the neuromodulation devices market are Medtronic, Inc. (U.S.), Cyberonics, Inc. (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical (U.S.), Enteromedics, Inc (U.S.), Neuropace, Inc (U.S.), Zynex, Inc (U.S.) and Neuronetics, Inc (U.S.). The emerging players in this market are Functional Neuromodulation, Ltd (U.S.), Microtransponder (U.S.), and Neurosigma, Inc (U.S.). For more information visit http://www.researchandmarkets.com/research/s7...modulation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Zynex Updates Financial Outlook for 2013
Marketwire - Fri Jul 12, 2:25PM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced today the Company's updated financial outlook for the remainder of 2013.
(0)
(0)Zynex Inc (ZYXI) Stock Research Links
Scroll down for more posts ▼